Characteristics and trends of globally registered glioma clinical trials in the past 16 years

Background: Advancement in the treatment of glioma has been vacant since temozolomide has proved its therapeutic value in glioblastoma in 2005. Aim: To help investigators understand the landscape of glioma clinical research, we analyzed the characteristics and trends of globally registered glioma tr...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic advances in neurological disorders 2022, Vol.15, p.17562864221114355-17562864221114355
Main Authors: He, Xiaofang, Zhao, Wenbin, Huang, Jianwen, Xu, Jia, Niu, Shaoqing, Zhang, Qun, Zhang, Nu, Jin, Huawei, Shen, Guoping
Format: Article
Language:English
Subjects:
Bayesian analysis
Brain tumors
Chemotherapy
Clinical trials
Cytotoxicity
Drug development
Drug therapy
Drugs
Glioblastoma
Glioma
Immune checkpoint inhibitors
Immunomodulation
Immunosuppressive agents
Immunotherapy
Original Research
Patients
Radiation therapy
Temozolomide
Trends
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Advancement in the treatment of glioma has been vacant since temozolomide has proved its therapeutic value in glioblastoma in 2005. Aim: To help investigators understand the landscape of glioma clinical research, we analyzed the characteristics and trends of globally registered glioma trials in the past decades. Methods: This is a cross-sectional analysis of glioma trials registered on ClinicalTrials.gov between January 2006 and December 2021. Characteristics regarding phase, enrollment number, study design and type, funding source, tumor site, pathology, patient status, age of population, trial purpose, and participating country were abstracted, and chronological shifts were analyzed. Results: There were 1531 registered glioma trials involved 58 participating countries. The trial purpose concerning surgery, radiotherapy, chemotherapy, targeted therapy, tumor-treating fields, immunotherapy, other antiglioma therapy and non-antiglioma research trial accounts for 3.5%, 6.5%, 9.5%, 28.9%, 2.0%, 16.4%, 12.5%, and 20.6%, respectively. In the past 16 years, the numbers of chemotherapy and targeted therapy trials declined; tumor-treating fields and immune checkpoint inhibitor application trials sprang at the latter half period; Immunotherapy, other antiglioma therapy and non-antiglioma research trials escalated (all above ptrend 
ISSN:1756-2864
1756-2856
1756-2864
DOI:10.1177/17562864221114355